UniSens Universal GPCR Activity Sensor for Next Generation Drug Discovery
- Coordinator
- Isar Bioscience GmbH, Germany
- Runs
- 1 November 2023 to 31 October 2027
- Status
- Running
- EU funding
- €3.0m
- Total cost
- €3.0m
- Partners
- 8 organisations in 6 countries
- Type
- European Innovation Council
- Grant agreement
- 101131014
What the project is doing
In the project's own words, from its summary on CORDIS.
This project by a consortium of academic labs and small biotech companies concerns a new key innovation for the development of drugs targeting G protein-coupled receptors (GPCRs). GPCRs are the most important class of therapeutic targets, both for current drugs and those under development, covering about a third of the €1.2 trillion pharmaceutical market. Recent research has revealed that GPCRs do not function as simple on/off switches but instead can adopt multiple conformations leading to complex textures of downstream effects.
Functionally selective drugs modulate the GPCR structure to stimulate certain downstream pathways over others. In the search for this next generation of better drugs, the pharmaceutical industry currently employs multiple (10+) distinct GPCR assays, performed in non-identical cellular contexts, and misleading readouts from this approach contribute significantly to costly drug failure. Here we propose a radically new single-assay technology platform that will enable detection and functional classification of drug candidates with superior confidence compared to today's approaches.
Its unique design supports streamlined drug discovery from the test tube to the native disease-relevant cell, as well as the capacity to efficiently harness artificial intelligence (AI) in the design of better drugs. The technology is based upon highly informative fluorescent sensor reagents that react to different receptor conformations with subtle, flexible changes in their structure. In this Pathfinder project, our main objective is to demonstrate that the conformational fingerprints generated by these sensors correlate to specific cellular signalling profiles, i.e.
GPCR activity states (proof of principle). We believe that the UniSens platform will become the standard tool for early drug development and could be a game-changer in the search for safer, more effective drugs.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Isar Bioscience GmbH | Planegg | Germany | Coordinator |
| Interax Biotech AG | Schlieren | Switzerland | Associatedpartner |
| Innovative Bioimaging Sro | Prague | Czechia | Participant |
| Univerzita Karlova | Praha 1 | Czechia | Participant |
| Celtarys Research SL | Santiago De Compostela | Spain | Participant |
| Centre National De La Recherche Scientifique CNRS | Paris | France | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Third party |
| Stichting Vu | Amsterdam | Netherlands | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI